- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Selective PET imaging of CXCR4 using the Al18F-labeled antagonist LY2510924 ; day:11 ; month:12 ; year:2024 ; pages:1-16
European journal of nuclear medicine and molecular imaging ; (11.12.2024), 1-16
- Urheber
-
Spahn, Muriel Aline
Loy, Tom Van
Celen, Sofie
Koole, Michel
Deroose, Christophe M.
Cawthorne, Christopher
Vanduffel, Wim
Schols, Dominique
Bormans, Guy
Cleeren, Frederik
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00259-024-07025-w
- URN
-
urn:nbn:de:101:1-2502230601048.059148075506
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:30 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Spahn, Muriel Aline
- Loy, Tom Van
- Celen, Sofie
- Koole, Michel
- Deroose, Christophe M.
- Cawthorne, Christopher
- Vanduffel, Wim
- Schols, Dominique
- Bormans, Guy
- Cleeren, Frederik
- SpringerLink (Online service)
Ähnliche Objekte (12)
Biodistribution of 99mTc Labeled Integrin Antagonist
CCR5 and CXCR4 antagonist and agonist binding sites
Discovery and characterization of an endogenous CXCR4 antagonist
Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model
Targeting of CXCR4 by the naturally occurring CXCR4 antagonist EPI-X4 in waldenström’s macroglobulinemia
Targeting CXCR4/CXCL12 axis via [177Lu]Lu-DOTAGA.(SA.FAPi)2 with CXCR4 antagonist in triple-negative breast cancer
A simple approach to 18F-labeled PSMA-selective ligands for PET imaging of prostate cancer recurrence
Finally an oral V2 selective vasopressin antagonist
Preparation and preliminary evaluation of a tritium-labeled allosteric P2X4 receptor antagonist
Absence of the CXCR4 antagonist EPI‑X4 from pharmaceutical human serum albumin preparations
Absence of the CXCR4 antagonist EPI-X4 from pharmaceutical human serum albumin preparations
Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery
Biodistribution of 99mTc Labeled Integrin Antagonist
CCR5 and CXCR4 antagonist and agonist binding sites
Discovery and characterization of an endogenous CXCR4 antagonist
Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model
Targeting of CXCR4 by the naturally occurring CXCR4 antagonist EPI-X4 in waldenström’s macroglobulinemia
Targeting CXCR4/CXCL12 axis via [177Lu]Lu-DOTAGA.(SA.FAPi)2 with CXCR4 antagonist in triple-negative breast cancer
A simple approach to 18F-labeled PSMA-selective ligands for PET imaging of prostate cancer recurrence
Finally an oral V2 selective vasopressin antagonist
Preparation and preliminary evaluation of a tritium-labeled allosteric P2X4 receptor antagonist
Absence of the CXCR4 antagonist EPI‑X4 from pharmaceutical human serum albumin preparations
Absence of the CXCR4 antagonist EPI-X4 from pharmaceutical human serum albumin preparations
Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery
Biodistribution of 99mTc Labeled Integrin Antagonist
CCR5 and CXCR4 antagonist and agonist binding sites
Discovery and characterization of an endogenous CXCR4 antagonist
Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model
Targeting of CXCR4 by the naturally occurring CXCR4 antagonist EPI-X4 in waldenström’s macroglobulinemia
Targeting CXCR4/CXCL12 axis via [177Lu]Lu-DOTAGA.(SA.FAPi)2 with CXCR4 antagonist in triple-negative breast cancer
A simple approach to 18F-labeled PSMA-selective ligands for PET imaging of prostate cancer recurrence
Finally an oral V2 selective vasopressin antagonist
Preparation and preliminary evaluation of a tritium-labeled allosteric P2X4 receptor antagonist
Absence of the CXCR4 antagonist EPI‑X4 from pharmaceutical human serum albumin preparations
Absence of the CXCR4 antagonist EPI-X4 from pharmaceutical human serum albumin preparations